RLAY: Relay Pharma Company Assets

Symbol and logo of brand Relay Pharma (RLAY)

Relay Therapeutics (RLAY) is developing a biopharmaceutical complex for targeted cancer treatment using the Dynamo digital system. The asset's market valuation trend reflects total assets at 848.28. Relay Therapeutics (RLAY) competes with industry behemoths for patents, overcoming the risks of discrepancies between virtual models and real-world tests. Massive capital and strict FDA regulations, combined with AI-driven protein analysis, create a powerful moat against new entrants.

Relay Therapeutics, Inc. (RLAY) Company Total Assets: for the period 07/04/2022 - 10/28/2026

Analytical breakdowns and data insights for company Relay Pharma (RLAY)

- price and consensus price forecast:
Market Price relaytx.com|RLAY - Price Target Chart
- market capitalization data:
Market Value Relay Corp|RLAY - Total Company Value
- book capitalization data:
Equity per Share Relay Therapeutics|RLAY - Book Capitalization|Market Cap to Net Assets Ratio relaytx.com|RLAY - Aggregate Company Assets
- debt and liquidity data:
Debt to Capital Relay Therapeutics|RLAY - Long-Term Debt to Equity|Short-Term Debt to Equity Relay Corp|RLAY - Company Debts|Debts to Book Value Relay Corp|RLAY - Company Long-Term Debts|Short-Term Indebtedness Relay Therapeutics
General company analysis:Relay Therapeutics
Finished products of Relay Corp

Total assets determine the investment stability of Relay Therapeutics (RLAY), reflecting aggregate capital via a reverse calculation from return on assets (ROA) to assess resource density. This chart of total assets allows for the correlation of drawdown risk with the value of intellectual property, where a unique AI protein modeling system provides the company with a strategic advantage in the development speed of oncology drugs.

Who Relay Therapeutics competes with

GMAB (genmab.com) - Company Assets|Aggregate Company Assets EXEL (Exelixis)|Company Assets NUVL|Aggregate Company Assets Kymera Therapeutics Inc KYMR|Total Business Assets IDEAYA Corp (IDYA)|Enliven Therapeutics - Company Total Assets|oricpharma.com - Cumulative Company Assets|NRIX (Nurix Therapeutics, Inc.) - Aggregate Company Assets|TYRA: Company Assets|Verastem Inc (VSTM) - Aggregate Company Assets|GLUE (Monte Rosa Corp) - Aggregate Company Assets|Aggregate Company Assets CGEM (Cullinan Therapeutics)|Company Assets immuneering.com|CCCC: Company Total Assets|Company Balance Sheet Assets Black Diamond Therapeutics, Inc. BDTX|RPTX: Cumulative Company Assets|PMVP - Company Assets|Cumulative Company Assets Karyopharm (KPTI)|Propanc Biopharma Inc (PPCB) - Aggregate Asset Value|BGMS - Cumulative Company Assets|Aadi Bioscience, Inc. (AADI) - Aggregate Business Assets|ALRN (Aileron Therapeutics Inc) - Company Total Assets|Company Total Assets BPMC|GlycoMimetics, Inc. (GLYC) - Aggregate Company Assets|Aggregate Asset Value springworkstx.com (SWTX)